Equity Distribution Agreements in the Biotechnology Industry

66 Contracts & Agreements

Browse by Company

AILERON THERAPEUTICS INC (1 contract)
Alector, Inc. (1)
ALPINE IMMUNE SCIENCES, INC. (1)
Altimmune, Inc. (2)
AMICUS THERAPEUTICS, INC. (1)
Applied Therapeutics Inc. (1)
Aptevo Therapeutics Inc. (2)
Aptose Biosciences Inc. (3)
Aravive, Inc. (1)
ATOSSA GENETICS INC (2)
Biohaven Pharmaceutical Holding Co Ltd. (1)
bluebird bio, Inc. (1)
CANCER GENETICS, INC (1)
CASI Pharmaceuticals, Inc. (1)
CATALYST BIOSCIENCES, INC. (1)
Cellectar Biosciences, Inc. (1)
Chelsea Worldwide Inc. (2)
ChemoCentryx, Inc. (1)
CTD HOLDINGS INC (1)
Denali Therapeutics Inc. (1)
DYNAVAX TECHNOLOGIES CORP (1)
Frequency Therapeutics, Inc. (1)
Genprex, Inc. (1)
HEMISPHERX BIOPHARMA INC (4)
HISTOGENICS CORP (1)
iBio, Inc. (2)
IDERA PHARMACEUTICALS, INC. (1)
Inhibikase Therapeutics, Inc. (1)
INOVIO PHARMACEUTICALS, INC. (0)
Isoray, Inc. (1)
LA JOLLA PHARMACEUTICAL CO (1)
MEI Pharma, Inc. (1)
Millendo Therapeutics, Inc. (1)
Nurix Therapeutics, Inc. (1)
OncoCyte Corp (1)
ONCOSEC MEDICAL Inc (1)
PALATIN TECHNOLOGIES INC (3)
PhaseBio Pharmaceuticals Inc (1)
PROGENITY, INC. (1)
SELLAS Life Sciences Group, Inc. (2)
Sorrento Therapeutics, Inc. (1)
SPHERIX INC (1)
Stellar Biotechnologies, Inc. (4)
T2 Biosystems, Inc. (3)
Tocagen Inc (1)
TYME TECHNOLOGIES, INC. (1)
XBiotech Inc. (1)
YIELD10 BIOSCIENCE, INC. (1)
ZIOPHARM ONCOLOGY INC (1)

Recent Contracts

Equity Distribution Agreement, dated July 26, 2024, by and between Aileron Therapeutics, Inc. and Citizens JMP Securities, LLC (AILERON THERAPEUTICS INC, Filed With SEC on July 26, 2024)
Amendment No. 1 to the Equity Distribution Agreement, dated July 11, 2024, by and between Nurix Therapeutics, Inc. and Piper Sandler & Co (Nurix Therapeutics, Inc., Filed With SEC on July 11, 2024)
Equity Distribution Agreement, dated July 1, 2024, by and between Biora Therapeutics, Inc., Canaccord Genuity LLC and H.C. Wainwright & Co., LLC (PROGENITY, INC., Filed With SEC on July 1, 2024)
Equity Distribution Agreement, dated as of April 19, 2023, by and between AIM Immunotech Inc. and Maxim Group LLC (HEMISPHERX BIOPHARMA INC, Filed With SEC on April 19, 2023)
Equity Distribution Agreement, dated April 12, 2023, between Palatin Technologies, Inc. and Canaccord Genuity LLC (PALATIN TECHNOLOGIES INC, Filed With SEC on April 12, 2023)
Equity Distribution Agreement, dated as of March 27, 2023, by and between Edesa Biotech, Inc. and Canaccord Genuity LLC (Stellar Biotechnologies, Inc., Filed With SEC on March 27, 2023)
Equity Distribution Agreement, dated January 23, 2023, by and between the Company and Maxim Group LLC (YIELD10 BIOSCIENCE, INC., Filed With SEC on January 24, 2023)
Amendment No. 1 to Equity Distribution Agreement, dated December 19, 2022, by and among Clene Inc. and Canaccord Genuity LLC and Oppenheimer & Co. Inc (Chelsea Worldwide Inc., Filed With SEC on December 20, 2022)
Equity Distribution Agreement, dated December 9, 2022, among Aptose Biosciences Inc. and JonesTrading Institutional Services LLC (Aptose Biosciences Inc., Filed With SEC on December 12, 2022)
Equity Distribution Agreement, dated November 18, 2022 by and among Genprex, Inc. and JMP Securities LLC (Genprex, Inc., Filed With SEC on November 18, 2022)
Equity Distribution Agreement, dated November 7, 2022, by and between Amicus Therapeutics, Inc. and Goldman Sachs & Co. LLC (AMICUS THERAPEUTICS, INC., Filed With SEC on November 7, 2022)
Equity Distribution Agreement, dated August 12, 2022, by and between Piper Sandler & Co. and the Registrant (ZIOPHARM ONCOLOGY INC, Filed With SEC on August 15, 2022)
Equity Distribution Agreement, dated as of June 22, 2022, by and between bluebird bio, Inc. and Goldman Sachs & Co. LLC (bluebird bio, Inc., Filed With SEC on June 22, 2022)
Equity Distribution Agreement, dated May 16, 2022, by and between Inhibikase Therapeutics, Inc. and Piper Sandler & Co (Inhibikase Therapeutics, Inc., Filed With SEC on May 17, 2022)
Equity Distribution Agreement, dated April 14, 2022, by and among Clene Inc. and Canaccord Genuity LLC and Oppenheimer & Co. Inc (Chelsea Worldwide Inc., Filed With SEC on April 14, 2022)
Equity Distribution Agreement, dated April 8, 2022, by and between Vyant Bio, Inc. and Canaccord Genuity LLC (CANCER GENETICS, INC, Filed With SEC on April 11, 2022)
First Amendment to Equity Distribution Agreement, dated as of March 4, 2022, by and between Edesa Biotech, Inc. and RBC Capital Markets, LLC (Stellar Biotechnologies, Inc., Filed With SEC on March 4, 2022)
Equity Distribution Agreement between the Company and Goldman Sachs & Co. LLC, SVB Securities LLC and Cantor Fitzgerald & Co., dated as of February 28, 2022 (Denali Therapeutics Inc., Filed With SEC on February 28, 2022)
Equity Distribution Agreement, dated January 26, 2022, by and between the Company and Cowen and Company, LLC (Applied Therapeutics Inc., Filed With SEC on January 26, 2022)
Equity Distribution Agreement, dated as of December 10, 2021, between Frequency Therapeutics, Inc. and Oppenheimer & Co. Inc (Frequency Therapeutics, Inc., Filed With SEC on December 10, 2021)
Equity Distribution Agreement, dated as of November 22, 2021, by and between Edesa Biotech, Inc. and RBC Capital Markets, LLC (Stellar Biotechnologies, Inc., Filed With SEC on November 22, 2021)
Equity Distribution Agreement, dated November 10, 2021 by and between PhaseBio Pharmaceuticals, Inc. and William Blair & Company, L.L.C (PhaseBio Pharmaceuticals Inc, Filed With SEC on November 10, 2021)
Equity Distribution Agreement, dated as of October 15, 2021, between Catalyst Biosciences, Inc. and Piper Sandler & Co (CATALYST BIOSCIENCES, INC., Filed With SEC on October 15, 2021)
Equity Distribution Agreement, dated as of August 16, 2021, between Cyclo Therapeutics, Inc. and Oppenheimer & Co. Inc (CTD HOLDINGS INC, Filed With SEC on August 16, 2021)
Equity Distribution Agreement, dated February 25, 2021, by and among Altimmune, Inc. and Piper Sandler & Co., Evercore Group L.L.C. and B. Riley Securities, Inc (Altimmune, Inc., Filed With SEC on February 25, 2021)
Equity Distribution Agreement, dated as of December 23, 2020, by and between Biohaven Pharmaceutical Holding Company Ltd. and Goldman Sachs & Co. LLC, Piper Sandler & Co., SVB... (Biohaven Pharmaceutical Holding Co Ltd., Filed With SEC on December 23, 2020)
Equity Distribution Agreement, dated December 14, 2020, between Aptevo Therapeutics Inc. and Piper Sandler & Co (Aptevo Therapeutics Inc., Filed With SEC on December 14, 2020)
Equity Distribution Agreement, dated as of September 28, 2020, by and between Edesa Biotech, Inc. and RBC Capital Markets, LLC (Stellar Biotechnologies, Inc., Filed With SEC on September 28, 2020)
Equity Distribution Agreement, dated as of September 25, 2020, by and between Atossa Therapeutics, Inc. and Maxim Group LLC (ATOSSA GENETICS INC, Filed With SEC on September 25, 2020)
Equity Distribution Agreement between Cellectar Biosciences, Inc. and Oppenheimer & Co. Inc., dated August 11, 2020 (Cellectar Biosciences, Inc., Filed With SEC on August 11, 2020)
Amendment No. 1 to Equity Distribution Agreement, dated July 29, 2020, by and between iBio, Inc. and UBS Securities LLC (iBio, Inc., Filed With SEC on July 29, 2020)
Equity Distribution Agreement, dated June 17 2020, by and between iBio, Inc. and UBS Securities, LLC (iBio, Inc., Filed With SEC on June 17, 2020)
Equity Distribution Agreement, dated May 13, 2020, by and among Alector, Inc., Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC (Alector, Inc., Filed With SEC on May 13, 2020)
Equity Distribution Agreement, dated May 5, 2020, among Aptose Biosciences Inc., Piper Sandler & Co. and Canaccord Genuity LLC (Aptose Biosciences Inc., Filed With SEC on May 5, 2020)
Amendment No. 2 to Equity Distribution Agreement dated as of April 8, 2020 by and between T2 Biosystems, Inc. and Canaccord Genuity LLC (T2 Biosystems, Inc., Filed With SEC on April 8, 2020)
Equity Distribution Agreement between Isoray, Inc. and Oppenheimer & Co. Inc., dated March 31, 2020 (Isoray, Inc., Filed With SEC on April 6, 2020)
Equity Distribution Agreement, dated March 27, 2020, by and among Altimmune, Inc. and JMP Securities LLC (Altimmune, Inc., Filed With SEC on March 27, 2020)
Equity Distribution Agreement, dated March 20, 2020 (OncoCyte Corp, Filed With SEC on March 20, 2020)
Amendment No. 1 to Equity Distribution Agreement dated as of March 9, 2020 by and between T2 Biosystems, Inc. and Canaccord Genuity LLC (T2 Biosystems, Inc., Filed With SEC on March 10, 2020)
Amended and Restated Equity Distribution Agreement, dated March 4, 2020, by and among the Company, Citigroup Global Markets Inc. and SVB Leerink LLC (Millendo Therapeutics, Inc., Filed With SEC on March 4, 2020)